Journal article
MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies
Abstract
BACKGROUND: To investigate whether microRNAs are predictive of sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in patients with metastatic colorectal cancer (mCRC).
METHODS: A total of 183 mCRC cases from 2 independent cohorts (cohort 1: 74 cases; validation cohort: 109 cases) treated with cetuximab or panitumumab were included in the study. MiRNA arrays were analyzed using Agilent's miRNA platform.
Authors
Cappuzzo F; Sacconi A; Landi L; Ludovini V; Biagioni F; D'Incecco A; Capodanno A; Salvini J; Corgna E; Cupini S
Journal
Clinical Colorectal Cancer, Vol. 13, No. 1, pp. 37–45.e4
Publisher
Elsevier
Publication Date
3 2014
DOI
10.1016/j.clcc.2013.11.006
ISSN
1533-0028
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiomarkers, TumorCetuximabColorectal NeoplasmsDisease-Free SurvivalDrug Resistance, NeoplasmErbB ReceptorsFemaleHumansKaplan-Meier EstimateMaleMicroRNAsMiddle AgedOligonucleotide Array Sequence AnalysisPanitumumabProportional Hazards ModelsTranscriptome